PY2117301A - Compuestos para su uso en infecciones víricas - Google Patents

Compuestos para su uso en infecciones víricas

Info

Publication number
PY2117301A
PY2117301A PY202102117301A PY2117301A PY2117301A PY 2117301 A PY2117301 A PY 2117301A PY 202102117301 A PY202102117301 A PY 202102117301A PY 2117301 A PY2117301 A PY 2117301A PY 2117301 A PY2117301 A PY 2117301A
Authority
PY
Paraguay
Prior art keywords
compounds
viral infections
virus
treatment
viral infection
Prior art date
Application number
PY202102117301A
Other languages
English (en)
Inventor
Losada González Alejandro
María Fernández- Sousa José
Avilés Marín Pablo
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PY2117301A publication Critical patent/PY2117301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de compuestos en el tratamiento de una infección vírica, en donde el virus se selecciona entre la familia Orthomyxoviridae o en donde el virus es el virus del Nilo occidental.
PY202102117301A 2020-03-02 2021-03-02 Compuestos para su uso en infecciones víricas PY2117301A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25

Publications (1)

Publication Number Publication Date
PY2117301A true PY2117301A (es) 2022-08-09

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
PY202102117308A PY2117308A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias
PY202102117301A PY2117301A (es) 2020-03-02 2021-03-02 Compuestos para su uso en infecciones víricas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PY202102117308A PY2117308A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias

Country Status (17)

Country Link
US (2) US20230295236A1 (es)
EP (2) EP4114435A1 (es)
JP (2) JP2023517535A (es)
KR (2) KR20220151643A (es)
CN (2) CN115666616A (es)
AU (2) AU2021232535A1 (es)
BR (2) BR112022016604A2 (es)
CA (2) CA3169544A1 (es)
CL (2) CL2022002396A1 (es)
CO (2) CO2022014031A2 (es)
IL (2) IL296069A (es)
MX (2) MX2022010926A (es)
PE (2) PE20230606A1 (es)
PY (2) PY2117308A (es)
TW (2) TW202144381A (es)
UY (2) UY39109A (es)
WO (2) WO2021175831A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021175826A1 (en) * 2020-03-02 2021-09-10 Pharma Mar, S.A. Compounds for use in the treatment of coronavirus infection
CA3169544A1 (en) * 2020-03-02 2021-09-10 Pablo Aviles Marin Compounds for use in inflammatory conditions
JP2023517194A (ja) * 2020-03-02 2023-04-24 ファルマ、マール、ソシエダード、アノニマ コロナウイルス感染の処置における組合せに使用するためのｐｌｄ
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CN1297352A (zh) * 1998-04-14 2001-05-30 哈桑·朱马 有机磷化合物在治疗和预防性治疗感染中的应用
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CA2430897C (en) * 2000-12-07 2010-11-16 Universiteit Utrecht Holding B.V. Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders
EP1596823A2 (en) * 2003-02-21 2005-11-23 Sun Pharmaceuticals Industries Ltd. A stable ophthalmic composition
CA2519234A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
CN101389347B (zh) * 2006-02-28 2013-03-27 法马马有限公司 提高的抗肿瘤治疗
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
SG10201501980SA (en) * 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
WO2016044095A1 (en) * 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CA3169544A1 (en) * 2020-03-02 2021-09-10 Pablo Aviles Marin Compounds for use in inflammatory conditions

Also Published As

Publication number Publication date
EP4114433A2 (en) 2023-01-11
US20230295236A1 (en) 2023-09-21
IL296068A (en) 2022-11-01
TW202146038A (zh) 2021-12-16
AU2021232535A1 (en) 2022-10-06
PE20230606A1 (es) 2023-04-10
MX2022010921A (es) 2022-09-29
KR20220151643A (ko) 2022-11-15
CN115461067A (zh) 2022-12-09
UY39109A (es) 2021-09-30
CA3169544A1 (en) 2021-09-10
CL2022002395A1 (es) 2023-06-30
CN115666616A (zh) 2023-01-31
TW202144381A (zh) 2021-12-01
JP2023517536A (ja) 2023-04-26
US20230159594A1 (en) 2023-05-25
TWI908772B (zh) 2025-12-21
EP4114435A1 (en) 2023-01-11
KR20220150350A (ko) 2022-11-10
WO2021175831A2 (en) 2021-09-10
IL296069A (en) 2022-11-01
BR112022016604A2 (pt) 2022-10-11
JP2023517535A (ja) 2023-04-26
BR112022016675A2 (pt) 2022-10-11
PY2117308A (es) 2022-08-09
CL2022002396A1 (es) 2023-06-30
WO2021175831A3 (en) 2021-10-14
AU2021231197A1 (en) 2022-10-06
PE20230412A1 (es) 2023-03-07
MX2022010926A (es) 2022-09-29
UY39110A (es) 2021-09-30
CA3169540A1 (en) 2021-09-10
CO2022014031A2 (es) 2022-10-21
WO2021175857A1 (en) 2021-09-10
CO2022014093A2 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
CO2022014031A2 (es) Compuestos para su uso en infecciones víricas
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
CL2018001207A1 (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
GT201300093A (es) Compuestos antivirales
ECSP14013315A (es) Inhibidores de aplicación viral
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
DOP2013000185A (es) Compuestos antivirales
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
MX381896B (es) Compuestos de tiazolida para el tratamiento de infecciones virales.
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CU20200009A7 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b
CO2019011305A2 (es) Tratamiento de una infección vaginal bacteriana
MX2022008062A (es) Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d.